Publication date: Dec 20, 2024
Background: Although COVID-19 is a known risk factor for thrombotic conditions including embolism, stroke, and myocardial infarction, stroke incidence after implementation of thromboprophylaxis during COVID-19 hospitalization in 2021 and how incidence may differ from influenza is unknown. Methods: PCORnet and HealthVerity (HV) data assets were used to identify patients aged [≥]65 years with no prior stroke and COVID-19 or influenza during January 1-December 31, 2022, and AIS from 3 days before to 28 days after COVID-19 or influenza diagnosis. Overall demographic information (age [for HV], sex, race/ethnicity), underlying conditions, level of care, outcomes, and incidence were described and compared between those with early (-3 to 7 days from diagnosis date) and late (8 to 28 days) AIS. Results: Among 245,352 (PC) and 639,396 (HV) patients aged [≥]65 years with COVID-19, the incidence of ischemic stroke in the 3 days prior to 7 days after diagnosis of COVID-19 (PC: 962/100,000 and HV: 447/100,000) and influenza (PC: 589/100,000 and HV: 387/100,000) was significantly higher than in the 8 to 28 days after diagnosis (COVID PC: 81/100,000 and HV: 141/100,000)(influenza PC:75/100,000 and HV: 15/100,000)(all P
Concepts | Keywords |
---|---|
100000influenza | Atlanta |
Influenza | Cdc |
Texas | Copyright |
Therapy | Covid |
Days | |
Diagnosis | |
Incidence | |
Influenza | |
Ischemic | |
License | |
Medrxiv | |
Pc | |
Phd | |
Preprint | |
Stroke |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | acute ischemic stroke |
disease | MESH | COVID-19 |
disease | MESH | influenza |
disease | MESH | embolism |
disease | MESH | stroke |
disease | MESH | myocardial infarction |
drug | DRUGBANK | Methylphenidate |
disease | MESH | Respiratory Diseases |
drug | DRUGBANK | Acetylsalicylic acid |
drug | DRUGBANK | Oxygen |
disease | MESH | Death |
drug | DRUGBANK | Oseltamivir |